Pretreatment of chicken embryo cells with homologous but not heterologous interferon inhibits the synthesis of vaccinia virus early messenger ribonucleic acid (mRNA). This inhibition is seen in the presence of cycloheximide, i.e., in the absence of protein synthesis, suggesting that the virion-bound transcriptase may be the target of the antiviral activity associated with interferon treatment. The inhibition of viral mRNA synthesis is dependent on the amount of chicken interferon used. The nonviral interferon inducer, polyriboinosine polyribocytidine, similarly inhibits viral early mRNA synthesis in a dose-specific manner. The helical polynucleotide polydeoxyinosine-polyribocytidine, which is not an effective interferon inducer in chicken embryo cells, has no effect on viral ribonucleic acid synthesis. 
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Recent experiments by Marcus et al. (P. I.
Marcus et al., Science, in press) demonstrate that the virion-bound transcriptase of vesicular stomatitis virus (VSV) is inhibited in vivo by pretreatment of the cells with interferon. Since vaccinia virus also contains a virion-bound transcriptase (13) and since the replication of vaccinia virus in the cytoplasm of infected cells is sensitive to the antiviral action of interferon (10), we have tested the sensitivity of the vaccinia transcriptase in vivo to pretreatment of the cells with two interferon preparations and with helical polynucleotides.
MATERIALS AND METHODS
Chicken interferon was prepared from the medium of Sindbis virus-infected aged chicken embryo fibroblasts (1) by the method of Lampson et al. (14) . Mouse interferon was prepared by the same method from the medium of mouse L cells infected with ultraviolet (UV)-irradiated Newcastle disease virus. The plaque reduction assay (1 PR50 unit = the concentration of interferon that reduces the plaque titer of a challenge virus by 50%) was used with both interferons; vaccinia was the challenge virus in the case of chicken interferon, and VSV was the challenge virus for mouse interferon.
Vaccinia virus (strain WR) was grown in suspension cultures of HeLa cells and purified by the method of Joklik (8) . The virus was plaque-titered on chicken embryo cells. Vaccinia deoxyribonucleic acid (DNA) was prepared from purified virions by the method of Kates and Beeson (11) . The methods for preparing pulse-labeled vaccinia virus ribonucleic acid (RNA) from the cytoplasm of infected cells and for hybridizing this RNA to vaccinia DNA have been described (3, 5) .
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a Interferons in the amounts indicated in the table were added to 100-mm dishes of confluent chicken embryo cultures in 8 ml of NCl medium (Schwartz BioResearch)) containing 2% heated calf serum. After incubation for 24 hr at 39 C to allow the establishment of the interferon block, the medium was removed and 8 ml of NCl i 2% heated calf serum containing 50,ug of cycloheximide per ml was added to the cultures. The dishes were incubated for 10 min at 37 C, after which the medium was removed and 0.8 ml of NCl plus 2% heated calf serum plus cycloheximide (50 ,g/ml) plus vaccinia virus strain WR was added. The virus was allowed to adsorb to the cells for 30 min at 37 C. The medium was replaced and incubation continued for an additional 60 min, after which the medium was removed from all plates and 2 ml of a labeling solution, containing NCl plus 2% dialyzed calf serum, 50,ug of cycloheximide per ml, and 100l,Ci of 3H-uridine per ml was added.
The dishes were incubated at 37 C for 12 min with agitation every 5 min and then transferred to an ice-slurry. The labeling solution was removed and the plates were washed with 5 ml of ice cold phosphate-buffered saline (PBS). An additional 5 ml of cold PBS was then added and the cells were removed from the plate with a rubber policeman. The plates were washed with cold PBS and the combined suspension of cells was centrifuged for 3 min at 2,000 rev/min. The cellular pellet was resuspended in 2 ml of cold hypotonic buffer of the following composition: 0.025 M KCl, 0.002 M MgCl2, 0.005 M CaCl2, 0.01 M tris(hydroxymethyl)aminomethane (Tris)-hydrochloride (pH 7.4), 0.1% Triton X-100, and allowed to swell on ice for 5 to 10 min before being gently dounced 12 to 15 times. Nuclei and cellular debris were removed by centrifugation and to the supernatants were added sodium dodecyl sulfate, (0.5% final concentration) and Pronase (0.5 mg/ml final concentration). After incubation at 37 C for 30 min, the solutions were extracted three times with phenol, and the ribonucleic acid (RNA) was precipitated by the addition of 2 inhibits the viral enzyme by 50I, whereas pretreatment of the cells with 1,000 units of heterologous mouse interferon has no effect on early vaccinia virus RNA synthesis. We then treated chicken cells with various concentrations of interferon, infected then with vaccinia virus in the presence of cycloheximide, and extracted the pulse-labeled cytoplasmic RNA as before. This RNA was then subjected to gel filtration on a 6% agarose column. The low-molecularweight RNA is retarded on such a column, whereas vaccinia mRNA appears in the void volume (3). The results presented in Table 2 show the dose-dependent inhibition of vaccinia virus early mRNA synthesis by pretreatment with interferon. We routinely find 80 to 85% inhibition of early mRNA synthesis by pretreatment with 320 units of chicken interferon when the RNA is purified in this manner.
A trivial explanation of these results is that interferon pretreatment and vaccinia virus infection markedly alters the intracellular pools of uridine, rendering the incorporation of 3H-uridine into acid-insoluble material an inaccurate measure of RNA synthesis. We therefore measured the soluble intracellular pools of uridine under the experimental conditions described above and found fluctuations of less than 10c. These data are presented in Table 3 A further indication that the inhibition of early mRNA synthesis is mediated by the interferon response comes from experiments using the nonviral interferon inducer, poly (rI) -poly (rC). The results presented in Table 5 show that pretreatment with increasing amounts of (rI),-(rC), inhibits the synthesis of early viral mRNA. An additional control was included in this experiment, namely a helical polynucleotide homopolymer pair, (dl)n-(rC)n, which is not an effective interferon inducer in these cells (2) and which did not reduce the level of viral mRNA.
DISCUSSION
The results of our experiments indicate that pretreatment of chicken embryo cells with interferon markedly reduces the synthesis of vaccinia virus early mRNA. This is in contrast with the results reported by Joklik and Merigan (10), who found no inhibition of pulse-labeled cytoplasmic RNA in interferon-treated mouse L cells infected with vaccinia virus. These conflicting results are 
